| bioTheranostics, Inc. Patent applications |
| Patent application number | Title | Published |
|---|
| 20130023441 | Identification of Tumors - The invention provides methods for the use of gene expression measurements to classify or identify tumors in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples. | 01-24-2013 |
| 20120196761 | DIAGNOSIS OF IN SITU AND INVASIVE BREAST CANCER - The disclosure includes the use of gene expression profiles, or patterns, with clinical relevance to breast cancer. In particular, the disclosure provides the identities of genes that are expressed in correlation with the presence of breast cancer, the grade of breast cancer, and the type of breast cancer. The disclosed methods assist in the detection and identification of breast cancer in a patient and so helps determine treatment and clinical outcome, and so prognosis, for the patient. The gene expression levels, whether embodied in nucleic acid expression, protein expression, or other expression formats, may be used detect the presence of in situ or invasive breast cancer. | 08-02-2012 |
| 20100047787 | PROSTATE CANCER SURVIVAL AND RECURRENCE - The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to prostate cancer. In particular, the disclosure is based on the identities of genes that are correlated with patient survival and prostate cancer recurrence. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats and used to predict the survival of subjects afflicted with prostate cancer and to predict prostate cancer recurrence. The profiles may also be used in the study and/or diagnosis of prostate cancer cells and tissue as well as for the study and/or determination of prognosis of a patient. When used for diagnosis or prognosis, the profiles may be used to determine the treatment of prostate cancer based upon probable life expectancy and cancer recurrence and/or metastasis. | 02-25-2010 |
